FI990171A - Novel compounds and compositions for the treatment of diseases related to tryptase activity - Google Patents
Novel compounds and compositions for the treatment of diseases related to tryptase activity Download PDFInfo
- Publication number
- FI990171A FI990171A FI990171A FI990171A FI990171A FI 990171 A FI990171 A FI 990171A FI 990171 A FI990171 A FI 990171A FI 990171 A FI990171 A FI 990171A FI 990171 A FI990171 A FI 990171A
- Authority
- FI
- Finland
- Prior art keywords
- compositions
- treatment
- novel compounds
- diseases related
- tryptase activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/14—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2313996P | 1996-07-30 | 1996-07-30 | |
| US89577297A | 1997-07-17 | 1997-07-17 | |
| PCT/US1997/013422 WO1998004537A1 (en) | 1996-07-30 | 1997-07-30 | Novel compounds and compositions for treating diseases associated with tryptase activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI990171A0 FI990171A0 (en) | 1999-01-29 |
| FI990171A true FI990171A (en) | 1999-03-23 |
Family
ID=26696778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI990171A FI990171A (en) | 1996-07-30 | 1999-01-29 | Novel compounds and compositions for the treatment of diseases related to tryptase activity |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0934293A1 (en) |
| JP (1) | JP2001509787A (en) |
| KR (1) | KR20000029679A (en) |
| CN (1) | CN1073103C (en) |
| AU (1) | AU733621B2 (en) |
| CA (1) | CA2262542A1 (en) |
| CZ (1) | CZ29799A3 (en) |
| EE (1) | EE9900036A (en) |
| FI (1) | FI990171A (en) |
| HU (1) | HUP0003267A3 (en) |
| LV (1) | LV12291B (en) |
| NO (1) | NO990433L (en) |
| NZ (1) | NZ333713A (en) |
| PL (1) | PL331465A1 (en) |
| SI (1) | SI9720047A (en) |
| SK (1) | SK8599A3 (en) |
| WO (1) | WO1998004537A1 (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221914B1 (en) | 1997-11-10 | 2001-04-24 | Array Biopharma Inc. | Sulfonamide bridging compounds that inhibit tryptase activity |
| EP1060171A2 (en) * | 1998-02-06 | 2000-12-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Tryptase inhibitors |
| PT1060175E (en) * | 1998-02-06 | 2005-03-31 | Max Planck Ges Ford Wissenscha | TRIPTASE INHIBITORS |
| CA2342855A1 (en) * | 1998-09-04 | 2000-03-16 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel pyranoses |
| SI1208089T1 (en) | 1999-08-10 | 2005-04-30 | Altana Pharma Ag | Diazocin-dione derivatives and their use as tryptase inhibitors |
| US6960588B1 (en) | 1999-09-14 | 2005-11-01 | Altana Pharma Ag | Tryptase inhibitors |
| WO2001036386A1 (en) * | 1999-11-17 | 2001-05-25 | Sumitomo Pharmaceuticals Co., Ltd. | Diabetic remedy containing dipiperazine derivative |
| DE19955476A1 (en) * | 1999-11-18 | 2001-05-23 | Boehringer Ingelheim Pharma | Bis-basic compounds as tryptase inhibitors, process for their preparation and their use as medicaments |
| JP2003518109A (en) * | 1999-12-20 | 2003-06-03 | アルタナ ファルマ アクチエンゲゼルシャフト | Tryptase inhibitor |
| US6815557B2 (en) | 1999-12-20 | 2004-11-09 | Altana Pharma Ag | Tryptase inhibitors |
| ES2225758T3 (en) | 2001-01-31 | 2005-03-16 | Altana Pharma Ag | DIAZOCINE DERIVATIVES AND ITS USE AS INHIBITING AGENTS OF TRIPTASE. |
| WO2002066420A2 (en) * | 2001-02-21 | 2002-08-29 | Altana Pharma Ag | Tryptase inhibitors |
| ES2278913T3 (en) | 2001-02-21 | 2007-08-16 | Altana Pharma Ag | INHIBITING AGENTS OF TRIPTASAS. |
| WO2002074732A2 (en) * | 2001-03-15 | 2002-09-26 | Altana Pharma Ag | Tryptase-inhibitors |
| US20040087792A1 (en) * | 2001-03-15 | 2004-05-06 | Thomas Martin | Tryptase-inhibitors |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| JP2004534057A (en) | 2001-06-11 | 2004-11-11 | ゼノポート，インコーポレイティド | GABA analog prodrug in oral dosage form with low toxicity |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| AU2002314165B2 (en) | 2001-06-19 | 2008-02-21 | Altana Pharma Ag | Tryptase inhibitors |
| JP2008518971A (en) | 2004-11-04 | 2008-06-05 | ゼノポート，インコーポレイティド | Gabapentin prodrug sustained release oral drug |
| US8399519B2 (en) * | 2008-12-19 | 2013-03-19 | Merz Pharma Gmbh & Co. Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases |
| TWI432188B (en) | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases |
| FR3038605B1 (en) | 2015-07-06 | 2018-08-24 | Universite Amiens Picardie Jules Verne | VICINAL PRIMARY DIAMINS ASSOCIATED WITH CHELATING MOTIFS OF METALS AND / OR FREE RADICALS, ACTIVE AGAINST CARBONYL AND OXIDIZING STRESSES AND THEIR USE |
| JP7373191B2 (en) * | 2017-05-12 | 2023-11-02 | 国立研究開発法人理化学研究所 | Class A GPCR-binding compound variants |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4845242A (en) * | 1987-04-28 | 1989-07-04 | Georgia Tech Research Corporation | Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents |
| AU683459B2 (en) * | 1993-03-12 | 1997-11-13 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
| US5525623A (en) * | 1993-03-12 | 1996-06-11 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
| EP0763016B1 (en) * | 1994-06-01 | 2000-01-26 | Axys Pharmaceuticals, Inc. | Compositions and methods for treating mast-cell mediated conditions |
| EE03525B1 (en) * | 1994-09-23 | 2001-10-15 | Arris Pharmaceutical Corporation | Compositions for the treatment of mast cell-mediated inflammatory conditions |
| CA2216151A1 (en) * | 1995-03-24 | 1996-10-03 | Arris Pharmaceutical Corporation | Reversible protease inhibitors |
| TW438591B (en) * | 1995-06-07 | 2001-06-07 | Arris Pharm Corp | Reversible cysteine protease inhibitors |
-
1997
- 1997-07-30 CA CA002262542A patent/CA2262542A1/en not_active Abandoned
- 1997-07-30 EE EEP199900036A patent/EE9900036A/en unknown
- 1997-07-30 NZ NZ333713A patent/NZ333713A/en unknown
- 1997-07-30 CZ CZ99297A patent/CZ29799A3/en unknown
- 1997-07-30 AU AU39670/97A patent/AU733621B2/en not_active Ceased
- 1997-07-30 KR KR1019997000757A patent/KR20000029679A/en not_active Application Discontinuation
- 1997-07-30 JP JP50913698A patent/JP2001509787A/en active Pending
- 1997-07-30 SK SK85-99A patent/SK8599A3/en unknown
- 1997-07-30 CN CN97196877A patent/CN1073103C/en not_active Expired - Fee Related
- 1997-07-30 SI SI9720047A patent/SI9720047A/en unknown
- 1997-07-30 WO PCT/US1997/013422 patent/WO1998004537A1/en not_active Application Discontinuation
- 1997-07-30 HU HU0003267A patent/HUP0003267A3/en unknown
- 1997-07-30 PL PL97331465A patent/PL331465A1/en unknown
- 1997-07-30 EP EP97937066A patent/EP0934293A1/en not_active Withdrawn
-
1999
- 1999-01-29 FI FI990171A patent/FI990171A/en unknown
- 1999-01-29 NO NO990433A patent/NO990433L/en not_active Application Discontinuation
- 1999-02-18 LV LVP-99-27A patent/LV12291B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LV12291A (en) | 1999-06-20 |
| LV12291B (en) | 2000-04-20 |
| EE9900036A (en) | 1999-08-16 |
| NO990433L (en) | 1999-03-25 |
| EP0934293A1 (en) | 1999-08-11 |
| FI990171A0 (en) | 1999-01-29 |
| AU733621B2 (en) | 2001-05-17 |
| CN1226892A (en) | 1999-08-25 |
| CN1073103C (en) | 2001-10-17 |
| SK8599A3 (en) | 2000-03-13 |
| AU3967097A (en) | 1998-02-20 |
| JP2001509787A (en) | 2001-07-24 |
| PL331465A1 (en) | 1999-07-19 |
| CZ29799A3 (en) | 1999-06-16 |
| CA2262542A1 (en) | 1998-02-05 |
| KR20000029679A (en) | 2000-05-25 |
| NZ333713A (en) | 2000-12-22 |
| WO1998004537A1 (en) | 1998-02-05 |
| HUP0003267A3 (en) | 2002-02-28 |
| HUP0003267A2 (en) | 2001-06-28 |
| NO990433D0 (en) | 1999-01-29 |
| SI9720047A (en) | 1999-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI990171A (en) | Novel compounds and compositions for the treatment of diseases related to tryptase activity | |
| ATE179610T1 (en) | COMPOSITION FOR THE TREATMENT OF OVARIAN ESTROGEN-DEPENDENT DISEASES | |
| IL135951A0 (en) | Antimutagenic compositions for the treatment and prevention of photodamage to skin | |
| FI953180A0 (en) | Compositions for the treatment of diabetic complications | |
| DE69739583D1 (en) | TOPICAL COMPOSITIONS CONTAIN AS A THERAPEUTICALLY ACTIVE AGENT A MONOGLYCERIDE FOR THE TREATMENT OF SLEW-TONE INFECTIONS | |
| FI972387A (en) | Parasiticidal compositions for application to the skin | |
| DE69117117D1 (en) | Cleaning composition for the prevention and alleviation of skin irritation | |
| ATE262331T1 (en) | HETEROCYCLIC VINYL ETHERS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
| DE69812784D1 (en) | Composition for the prevention and elimination of plant diseases | |
| HU9502918D0 (en) | Pharmaceutical composition of antihypertriglyceridemic activity | |
| DE69841984D1 (en) | COMPOSITION OF NANOCAPSULES FOR THE TREATMENT OF INTRAARTICULAR DISEASES | |
| PL332430A1 (en) | Skin care compositions containing combinations of compounds capable to simulate the action of retinic acid onto skin | |
| EE04055B1 (en) | Compounds and compositions for the treatment of diseases associated with serine protease activity, in particular tryptase activity, and their use | |
| FI965204A (en) | Medical use of bromelain | |
| DE69620691D1 (en) | Therapeutic agent for the treatment of hypercholesterolemia | |
| BR9711225A (en) | Transdermal propentophylline compositions for the treatment of alzheimer's disease | |
| DE69405919D1 (en) | Compositions for the treatment of keratin fibers | |
| HUP9904317A3 (en) | Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases | |
| DE69807466D1 (en) | TRIPTOLID DERIVATIVES USEFUL FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| HUP0104963A3 (en) | Compositions for the treatment of skin diseases | |
| AU4376396A (en) | Use of andrographolide compounds to treat or prevent pathogenicity of diseases | |
| ID25765A (en) | COMPOSITION OF SKIN CLEANER | |
| DE69822297D1 (en) | TRIPTOLID DERIVATIVES SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| ID23175A (en) | THE USE OF BENZOPIRANOL TO TREAT NERVE DISORDERS | |
| DE69913380D1 (en) | COMPOSITION FOR THE TREATMENT OF PERIODONTAL DISEASES |